

**BUY**

TP: Rs 7,500 | ▲ 17%

**DIVI'S LABS**

| Pharmaceuticals

| 11 February 2026

## LoE risk now behind Custom Synthesis business

- Sales/EBITDA/APAT were -5%/-1.5%/-7.3% below our estimates. EBITDA Margin were 122 bps above our estimates
- Custom Synthesis segment to continue to grow in double digits (ex of 3 Long Term Supply Agreements), despite LOE of key molecule
- Continue to ascribe similar PE of 56x and rolling forward to Dec'27 EPS, arrive at PT of Rs 7500, implying 16% upside; thus upgrade to BUY

**Foram Parekh**  
Research Analyst  
research@bobcaps.in

**In-line result** – Divi's reported in-line set of numbers with sales growing 12% YoY (8% in constant currency terms) driven by 23% YoY growth in Custom Synthesis and 1% YoY growth in Generics (4% decline in Generics API; 26% YoY growth in Nutraceuticals). A Healthy product mix and RM cost rationalization (36% contribution in 3QFY26 vs 40% in 3QFY25) led to increase in Gross Margin to 64% (60% historically). Consequently, EBITDA Margin increased by 213 bps to 34.2% qith EBITDA growth of 19%. During the quarter, there was an exceptional cost of Rs 740 mn attributable to a one-time labour code impact, resulting in 1% decline in PAT, However, adjusting against this one-time cost, PAT grew by 11.5% YoY.

**Custom Synthesis sales increase despite key molecule LoE** – Divi's Custom Synthesis sales were 2% below our estimates at Rs 14.8bn. This segment contributed 57% of the sales, compared to 52% in 3QFY25 and 56% in 2QFY26. The company has indicated that multiple Custom Synthesis projects are in the validation stage and are expected to move into commercialization once innovators receive regulatory approval. Of the three long-term supply agreement projects, one commercial project is expected to be commercialized in 4QFY27. Management does not foresee significant risk from the genericization of its key molecule. Factoring in incremental sales from long-term supply agreements, we believe this segment to grow at a CAGR of 25% over FY26–28E and contribute 61% of total sales in FY28E, reaching Rs 87bn.

**Generic sales remain stable amid pricing pressure** – Generics segment reported 9% below our estimates at Rs 11.2bn. The miss was due to a 14% shortfall in the Nutraceuticals segment and an 8% shortfall in the API segment. The company witnessed healthy volume growth and customer retention, However, this was offset by value erosion. Due to persistent pricing pressure on generics, we expect this segment to grow at a CAGR of 8% over FY26–28E, reaching Rs 45.6bn in FY28E.

**Valuations** - Currently, the stock is trading at 49x on Dec'27 EPS and we continue to ascribe 56x (vs 1YF PE of 58x) and rollforward to Dev'27E EPS to arrive at a PT of Rs 7500 (earlier Rs 7098), implying 17% upside, thus upgrading the stock to Buy (earlier Hold).

## Key changes

Target	Rating
▲	▲

Ticker/Price	DIVI IN/Rs 6,387
Market cap	US\$ 18.7bn
Free float	48%
3M ADV	US\$ 22.9mn
52wk high/low	Rs 7,072/Rs 4,955
Promoter/FPI/DII	52%/15%/22%


Source: NSE | Price as of 11 Feb 2026

## Key financials

Y/E 31 Mar	FY25A	FY26E	FY27E
Total revenue (Rs mn)	93,600	103,078	118,065
EBITDA (Rs mn)	29,680	33,255	41,042
Adj. net profit (Rs mn)	21,910	25,104	30,609
Adj. EPS (Rs)	82.5	94.6	115.3
Consensus EPS (Rs)	82.5	96.8	118.6
Adj. ROAE (%)	15.4	16.4	18.3
Adj. P/E (x)	77.4	67.5	55.4
EV/EBITDA (x)	58.4	52.0	42.1
Adj. EPS growth (%)	39.6	14.6	21.9

Source: Company, Bloomberg, BOBCAPS Research

## Stock performance



Source: NSE



## Financial Highlights

**Fig 1 – Quarterly Highlights**

(Rs mn)	Q3FY26	Q3FY25	YoY (%)	Q2FY26	QoQ (%)	Q3FY26E	Var (%)
Net Sales	26,040	23,190	12.3	27,150	(4.1)	27,429	(5.1)
Total Expenses	17,140	15,760	8.8	18,270	(6.2)	18,391	(6.8)
(%) of net sales	65.8	68.0		67.3		67.1	
Raw material consumed	9,450	9,220	2.5	10,730	(11.9)	10,972	(13.9)
(%) of net sales	36.3	39.8		39.5		40.0	
Staff cost	3,670	2,970	23.6	3,540	3.7	3,511	4.5
(%) of net sales	14.1	12.8		13.0		12.8	
SG&A	4,020	3,570	12.6	4,000	0.5	3,909	2.8
(%) of net sales	15.4	15.4		14.7		14.3	
EBITDA	8,900	7,430	19.8	8,880	0.2	9,038	(1.5)
Depreciation	1,180	990	19.2	1,130	4.4	1,140	3.5
EBIT	7,720	6,440	19.9	7,750	(0.4)	7,898	(2.3)
Interest	60	0	-	80	(25.0)	80	(25.0)
Other Income	880	820	7.3	1,450	(39.3)	1,500	(41.3)
PBT	8,540	7,260	17.6	9,120	(6.4)	9,318	(8.3)
Less: Taxation	(1,970)	(1,370)	43.8	(2,230)	(11.7)	(2,230)	(11.7)
PAT	6,570	5,890	11.5	6,890	(4.6)	7,088	(7.3)
Less: Minority Interest	0	0	-	0	-	0	-
PAT attributable to shareholders	5,830	5,890	(1.0)	6,890	(15.4)	7,088	(17.7)
<b>Key Ratios (%)</b>							
Gross Margin	63.7	60.2	346.8bps	60.5	323.1bps	60.0	371.0bps
EBITDA Margin	34.2	32.0	213.9bps	32.7	147.1bps	33.0	122.8bps
Tax / PBT	23.1	18.9	419.7bps	24.5	(138.4bps)	23.9	(86.5bps)
NPM	22.4	25.4	(301.0bps)	25.4	(298.9bps)	25.8	(345.2bps)
EPS	22.0	22.2	(22.6bps)	26.0	(399.3bps)	26.7	(473.9bps)

Source: Company, BOBCAPS Research


**Fig 2 – Revenue Mix**

(Rs mn)	Q3FY26	Q3FY25	YoY (%)	Q2FY26	QoQ (%)	BoB estimate	Var (%)
Custom Synthesis	14,843	12,059	23.1	15,204	(2.4)	15,074	(1.5)
Generic Segment	11,197	11,131	0.6	11,946	(6.3)	12,356	(9.4)
API	9,057	9,431	(4.0)	9,526	(4.9)	9,856	(8.1)
Nutraceuticals	2,140	1,700	25.9	2,420	(11.6)	2,500	(14.4)
Total	26,040	23,190	12.3	27,150	(4.1)	27,429	(5.06)

Source: Company, BOBCAPS Research


## Financial Charts

**Fig 3 – Custom Synthesis sales rising amidst LoE of key molecule**




Source: Company, BOBCAPS Research

**Fig 4 – Generics sales lower due to pricing pressure**




Source: Company, BOBCAPS Research

**Fig 5 – Revenue growth driven by healthy Custom Synthesis sales**




Source: Company, BOBCAPS Research

**Fig 6 – EBITDA growth aided by better Gross Profit**




Source: Company, BOBCAPS Research

**Fig 7 – Margin increase due to backward integration**



Source: Company, BOBCAPS Research

**Fig 8 – APAT growth aided by better Other Income**



Source: Company, BOBCAPS Research

## Earnings Call highlights

### Outlook

- Operating environment expected to remain broadly stable over the next six months in terms of raw material pricing and availability.
- Multiple Custom Synthesis projects expected to commercialize by CY2027, supporting revenue diversification.
- Commercialization timeline for three dedicated CS projects anticipated in Q3–Q4 CY27, subject to timely regulatory approvals.
- Phase-II expansion at Kakinada (Unit 3) under consideration, potentially adding four new production blocks.
- Gross asset turnover expected to move toward historical levels (1.5x–1.8x) over the medium term, driven by revenue visibility from dedicated capex and pipeline commercialization in CS.
- FY26 CapEx (excluding disclosed dedicated CS projects) likely to remain in line with historical run rates.

### Operational & Financial Highlights

- **Exports:** ~89% of total sales; US + Europe contributed ~73% of export revenue.
- **Product Mix (Q3):** ~43% Generics, ~57% Custom Synthesis.
- **Procurement front:** Raw Material prices & Availability broadly stable during Q3.
- **Supply Chain:** Supply chain resilience supported by diversified vendor base and backward integration (especially Unit 3); Divis remain vigilant with respect to external developments that could influence input costs, including recent policy changes, such as China's withdrawal of export tax rebates on certain products, which may result in selective pricing pressures over time.
- **Reduced China dependency:** Procurement diversification increased domestic supplier contribution to 78% by quantity, reducing dependence on Chinese imports.
- **Focus:** Risk Management remains core focus area for the company.
- **Supplier Diversification:** Systematically expanding & qualifying additional suppliers while maintaining prudent inventory buffers to ensure continuity of operations.
- **Logistics Conditions:** Logistics conditions manageable during Q3 with freight rate largely stable, continue to work closely with long-standing logistics partners, plan shipments well in advance, & maintain transparency & communication with customers regarding delivery schedules.
- **Capacity utilization** at 70-80%; Unit-III at Kakinada produces pre-chemistry products will free existing GMP facility of Unit 1 & Unit 2.

**Generic Business-**

- **Performance:** Stable performance maintained supported by strong backward integration, process efficiencies, & ability to develop & deliver across regions.
- **Volume:** Healthy volume traction in select Emerging and Focus Markets despite competitive pricing.
- **API Generic:** Faces competitive pricing pressure impacting value growth despite volume increases.

**Custom Synthesis-**

- **RFP'S:** Actively engaged in several RFP'S and Customer visits.
- **Competitive positioning:** Competitive positioning strengthened by strong EHS track record, compliance readiness, scalable capacities, and reliable execution history.
- Engagement across early-stage, secondary sourcing, and late life-cycle molecules suggests diversified revenue streams, reduces concentration risk and helps in sustaining double-digit growth trajectory. Most of the Molecule Divis manufacture falls in Phase -3.

**Peptide Offering-**

- Long-standing expertise in peptide chemistry across platforms.
- Strong capabilities in complex building blocks and fragments.
- Decades of experience in protected amino acids ensure consistency and quality control.
- Supported multiple customer programs across all clinical phases during Q3.
- GLP-1 pilot plant completed; large-scale SPPS commercial facility (based on customer requirements) constructed and undergoing validation.
- Expanding peptide applications into psoriasis, anti-inflammatory, and cardiac segments.
- Commercial-scale SPPS and LPPS capabilities across pilot and commercial scale.
- Flexible in handling varying peptide chain lengths (10-mer to 18-mer and beyond).
- Manufactures peptide fragments for innovators (not generics), with regulatory requirements determined by the customer depending on the fragment's integration within the final peptide structure.

**Unit Updates****Unit 3 operations:**

- Key driver of backward integration strategy.
- Operational blocks focused on starting materials & intermediates, strengthening supply chain.

Expansion & transfer activities are still going on, with additional manufacturing blocks being progressed as planned

**Unit 1:**

Successful USFDA CGMP inspection at Nutraceutical facility, reinforces regulatory compliance strength

## Valuation methodology

We arrive at our Revenue/EBITDA/PAT CAGRs of 17%/22%/21%, respectively, over FY26–28E, driven by: 1) factoring in commercial supplies from one long-term supply agreement starting 4QFY27 (Asset Turnover ratio of 1.5x); 2) sustaining double-digit sales growth excluding long-term supply agreements; 3) normalized growth in the Generics segment; 4) benefits from backward integration of Unit 3; and 5) higher other income due to rupee depreciation.

We believe the street had already factored in the long-term supply agreement (LSA) for Custom Synthesis. However, the sustenance of double-digit growth in the segment excluding the LSA, even after the key molecule's LoE, is a significant positive for the stock. We also believe the increase in margins is likely to continue, supported by the ongoing benefits from backward integration of Unit 3 at the Kakinada plant, which has only completed Phase 1, however, we have trimmed it to moderate levels of 35% by FY28E due to unpredictable commodity prices.

Factoring in the above positives and increasing other income, we have marginally tweaked our EPS estimates by 0.7%/–2.2%/2.4% for FY26E/FY27E/FY28E, respectively. Currently, the stock is trading at 49x on Dec'27 EPS. We continue to ascribe a multiple of 56x (vs. 1YF PE of 58x) and roll forward to Dec'27E EPS to arrive at a PT of Rs 7,500 (earlier Rs 7,098), implying 17% upside, thereby upgrading the stock to Buy (earlier Hold).

**Fig 9 – Change in Estimates**

(Rs mn)	New			Old			Change (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Sales	103,078	118,065	142,066	100,271	115,061	133,162.0	2.8	2.6	6.7
EBITDA	33,255	41,042	49,803	34,355	43,450	50,285.0	(3.2)	(5.5)	(1.0)
EBITDA margin (%)	32.3	34.8	35.1	34.3	37.8	37.8	(200 bps)	(300 bps)	(271 bps)
EPS (Rs)	94.6	115.3	138.9	93.9	117.9	135.6	0.7	(2.2)	2.4

Source: Company, BOBCAPS Research


## Key Risks

Key downside risks to our estimates are:

- Lower than-expected revival in generic API business
- Delay in execution of 3 long term supply agreement
- Lower demand from innovators for GLP opportunities


## Valuation Bands

**Fig 10 – 1YF PE Band**




Source: Bloomberg

**Fig 11 – 1Y F EV/EBITDA Band**




Source: Bloomberg

**Fig 12 – 1YF P/BV Band**




Source: Bloomberg

**Fig 13 – 1YF EV/Sales Band**




Source: Bloomberg

**Fig 14 – Divis vs Nifty Pharma**



Source: Bloomberg

**Fig 15 – Divi's vs Nifty 50**



Source: Bloomberg



## Financials

### Income Statement

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
<b>Total revenue</b>	<b>78,450</b>	<b>93,600</b>	<b>103,078</b>	<b>118,065</b>	<b>142,066</b>
EBITDA	22,050	29,680	33,255	41,042	49,803
Depreciation	3,780	4,020	4,393	5,055	5,716
EBIT	18,270	25,660	28,862	35,987	44,087
Net interest inc./(exp.)	(30)	(20)	(230)	(200)	(150)
Other inc./(exp.)	3,090	3,520	4,400	4,488	4,578
Exceptional items	0	0	0	0	0
EBT	21,330	29,160	33,032	40,275	48,515
Income taxes	5,630	7,250	7,928	9,666	11,644
Extraordinary items	300	0	(740)	0	0
Min. int./Inc. from assoc.	0	0	0	0	0
<b>Reported net profit</b>	<b>16,000</b>	<b>21,910</b>	<b>24,364</b>	<b>30,609</b>	<b>36,871</b>
Adjustments	(300)	0	740	0	0
<b>Adjusted net profit</b>	<b>15,700</b>	<b>21,910</b>	<b>25,104</b>	<b>30,609</b>	<b>36,871</b>

### Balance Sheet

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Accounts payables	8,240	9,100	8,260	9,098	10,947
Other current liabilities	10,280	9,950	9,950	9,950	9,950
Provisions	440	540	594	653	719
Debt funds	30	40	230	200	150
Other liabilities	0	0	0	0	0
Equity capital	531	531	531	531	531
Reserves & surplus	134,380	149,160	156,670	176,820	201,092
Shareholders' fund	134,911	149,691	157,201	177,351	201,623
<b>Total liab. and equities</b>	<b>153,901</b>	<b>169,321</b>	<b>176,236</b>	<b>197,252</b>	<b>223,389</b>
Cash and cash eq.	39,000	37,371	29,064	32,927	34,808
Accounts receivables	21,560	27,310	28,241	32,347	38,922
Inventories	31,840	32,360	31,065	32,347	38,922
Other current assets	5,511	6,990	6,830	6,830	6,830
Investments	820	650	650	650	650
Net fixed assets	47,330	54,370	67,677	77,002	85,666
CWIP	7,780	10,220	12,660	15,100	17,540
Intangible assets	60	50	50	50	50
Deferred tax assets, net	0	0	0	0	0
Other assets	0	0	0	0	0
<b>Total assets</b>	<b>153,901</b>	<b>169,321</b>	<b>176,236</b>	<b>197,252</b>	<b>223,389</b>

### Cash Flows

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
<b>Cash flow from operations</b>	<b>14,598</b>	<b>19,551</b>	<b>28,727</b>	<b>31,372</b>	<b>31,501</b>
Capital expenditures	(9,605)	(16,810)	(16,820)	(16,820)	(16,820)
Change in investments	(50)	170	0	1	1
Other investing cash flows	0	0	0	0	0
<b>Cash flow from investing</b>	<b>(9,654)</b>	<b>(16,640)</b>	<b>(16,820)</b>	<b>(16,819)</b>	<b>(16,819)</b>
Equities issued/Others	0	0	0	0	0
Debt raised/repaid	25	10	190	0	0
Interest expenses	(30)	(20)	(230)	(200)	(150)
Dividends paid	0	0	0	0	0
Other financing cash flows	(9,676)	(7,850)	(16,854)	(10,460)	(12,599)
<b>Cash flow from financing</b>	<b>(9,681)</b>	<b>(7,860)</b>	<b>(16,894)</b>	<b>(10,660)</b>	<b>(12,749)</b>
<b>Chg in cash &amp; cash eq.</b>	<b>(4,737)</b>	<b>(4,948)</b>	<b>(4,987)</b>	<b>3,894</b>	<b>1,932</b>
<b>Closing cash &amp; cash eq.</b>	<b>39,000</b>	<b>34,051</b>	<b>29,064</b>	<b>32,958</b>	<b>34,859</b>

### Per Share

Y/E 31 Mar (Rs)	FY24A	FY25A	FY26E	FY27E	FY28E
Reported EPS	60.3	82.5	91.8	115.3	138.9
Adjusted EPS	59.1	82.5	94.6	115.3	138.9
Dividend per share	29.8	35.0	31.4	39.4	47.5
Book value per share	508.1	563.8	592.1	668.0	0.0

### Valuations Ratios

Y/E 31 Mar (x)	FY24A	FY25A	FY26E	FY27E	FY28E
EV/Sales	22.2	18.5	16.8	14.6	12.2
EV/EBITDA	78.8	58.4	52.0	42.1	34.7
Adjusted P/E	108.0	77.4	67.5	55.4	46.0
P/BV	12.6	11.3	10.8	9.6	

### DuPont Analysis

Y/E 31 Mar (%)	FY24A	FY25A	FY26E	FY27E	FY28E
Tax burden (Net profit/PBT)	73.6	75.1	76.0	76.0	76.0
Interest burden (PBT/EBIT)	116.7	113.6	114.4	111.9	110.0
EBIT margin (EBIT/Revenue)	23.3	27.4	28.0	30.5	31.0
Asset turnover (Rev./Avg TA)	13.1	14.5	14.9	15.8	16.9
Leverage (Avg TA/Avg Equity)	1.1	1.1	1.1	1.1	1.1
<b>Adjusted ROAE</b>	<b>11.9</b>	<b>15.4</b>	<b>16.4</b>	<b>18.3</b>	<b>19.5</b>

### Ratio Analysis

Y/E 31 Mar	FY24A	FY25A	FY26E	FY27E	FY28E
<b>YoY growth (%)</b>					
Revenue	1.0	19.3	10.1	14.5	20.3
EBITDA	(6.9)	34.6	12.0	23.4	21.3
Adjusted EPS	(7.6)	39.6	14.6	21.9	20.5

### Profitability & Return ratios (%)

EBITDA margin	28.1	31.7	32.3	34.8	35.1
EBIT margin	23.3	27.4	28.0	30.5	31.0
Adjusted profit margin	20.0	23.4	24.4	25.9	26.0
Adjusted ROAE	11.9	15.4	16.4	18.3	19.5
ROCE	11.4	14.8	15.9	18.9	20.3

### Working capital days (days)

Receivables	92	95	100	100	100
Inventory	144	125	110	100	100
Payables	93	85	75	75	75

### Ratios (x)

Gross asset turnover	1.1	1.1	1.0	1.0	1.1
Current ratio	5.2	5.3	5.1	5.3	5.5
Net interest coverage ratio	609.0	1,283.0	125.5	179.9	293.9
<b>Adjusted debt/equity</b>	<b>(0.3)</b>	<b>(0.3)</b>	<b>(0.2)</b>	<b>(0.2)</b>	<b>(0.2)</b>

Source: Company, BOBCAPS Research | Note: TA = Total Assets

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

## Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**

Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**

SEBI Research Analyst Registration No: **INH000000040 valid till 01 February 2030**

Brand Name: **BOBCAPS**

Trade Name: **www.barodaetrade.com**

CIN: **U65999MH1996GOI098009**



Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

### Recommendation scale: Recommendations and Absolute returns (%) over 12 months

**BUY** – Expected return >+15%


**HOLD** – Expected return from -6% to +15%

**SELL** – Expected return <-6%

**Note:** Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

### Ratings and Target Price (3-year history): DIVI'S LABS (DIVI IN)



B – Buy, H – Hold, S – Sell, A – Add, R – Reduce

### Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

### General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

#### **Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014**

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

#### **Other disclaimers**

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an “as is” basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the “Losses”) which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

#### **Distribution into the United Kingdom (“UK”):**

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd (“MSL”) who is authorised and regulated by the Financial Conduct Authority (“FCA”) in the United Kingdom (MSL and its affiliates are collectively referred to as “MAYBANK”). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the “Order”), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as “relevant persons”).

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

#### **No distribution into the US:**

This report will not be distributed in the US and no US person may rely on this communication.

#### **Other jurisdictions:**

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.